Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

923 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dynamic changes in peripheral lymphocytes and antibody response following a third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients.
Ruggeri EM, Nelli F, Giannarelli D, Fabbri A, Giron Berrios JR, Virtuoso A, Marrucci E, Mazzotta M, Schirripa M, Signorelli C, Chilelli MG, Primi F, Fiore C, Panichi V, Topini G, Silvestri MA. Ruggeri EM, et al. Among authors: fabbri a. Sci Rep. 2022 Dec 19;12(1):21908. doi: 10.1038/s41598-022-25558-8. Sci Rep. 2022. PMID: 36535985 Free PMC article.
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting.
Pizzuti L, Natoli C, Gamucci T, Mauri M, Sergi D, Di Lauro L, Paoletti G, Ruggeri E, Iezzi L, Sperduti I, Mentuccia L, Fabbri A, Maugeri-Saccà M, Moscetti L, Barba M, Vici P. Pizzuti L, et al. Among authors: fabbri a. Oncotarget. 2017 Apr 9;8(40):69025-69037. doi: 10.18632/oncotarget.16982. eCollection 2017 Sep 15. Oncotarget. 2017. PMID: 28978178 Free PMC article.
Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials.
Marinelli D, Mazzotta M, Pizzuti L, Krasniqi E, Gamucci T, Natoli C, Grassadonia A, Tinari N, Tomao S, Sperduti I, Sanguineti G, Botticelli A, Fabbri A, Botti C, Ciliberto G, Barba M, Vici P. Marinelli D, et al. Among authors: fabbri a. Cancers (Basel). 2020 Sep 3;12(9):2497. doi: 10.3390/cancers12092497. Cancers (Basel). 2020. PMID: 32899209 Free PMC article.
Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2- Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series.
Orlandi A, Iattoni E, Pizzuti L, Fabbri A, Botticelli A, Di Dio C, Palazzo A, Garufi G, Indellicati G, Alesini D, Carbognin L, Paris I, Vaccaro A, Moscetti L, Fabi A, Magri V, Naso G, Cassano A, Vici P, Giannarelli D, Franceschini G, Marchetti P, Bria E, Tortora G. Orlandi A, et al. Among authors: fabbri a. J Pers Med. 2020 Dec 18;10(4):291. doi: 10.3390/jpm10040291. J Pers Med. 2020. PMID: 33353132 Free PMC article.
Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study.
Nelli F, Fabbri A, Onorato A, Giannarelli D, Silvestri MA, Giron Berrios JR, Virtuoso A, Marrucci E, Signorelli C, Chilelli MG, Primi F, Schirripa M, Mazzotta M, Ruggeri EM. Nelli F, et al. Among authors: fabbri a. Ann Oncol. 2022 Jan;33(1):107-108. doi: 10.1016/j.annonc.2021.09.009. Epub 2021 Sep 20. Ann Oncol. 2022. PMID: 34555502 Free PMC article. No abstract available.
Six month immunogenicity of COVID-19 mRNA-BNT162b2 vaccine in actively treated cancer patients: updated results of the Vax-On study.
Nelli F, Fabbri A, Onorato A, Giannarelli D, Silvestri MA, Pessina G, Giron Berrios JR, Virtuoso A, Marrucci E, Schirripa M, Mazzotta M, Panichi V, Cercola P, Signorelli C, Chilelli MG, Primi F, Ruggeri EM. Nelli F, et al. Among authors: fabbri a. Ann Oncol. 2022 Mar;33(3):352-354. doi: 10.1016/j.annonc.2021.12.001. Epub 2021 Dec 10. Ann Oncol. 2022. PMID: 34896598 Free PMC article. No abstract available.
Antineoplastic treatment class modulates COVID-19 mRNA-BNT162b2 vaccine immunogenicity in cancer patients: a secondary analysis of the prospective Vax-On study.
Ruggeri EM, Nelli F, Fabbri A, Onorato A, Giannarelli D, Giron Berrios JR, Virtuoso A, Marrucci E, Mazzotta M, Schirripa M, Panichi V, Pessina G, Signorelli C, Chilelli MG, Primi F, Natoni F, Fazio S, Silvestri MA. Ruggeri EM, et al. Among authors: fabbri a. ESMO Open. 2022 Feb;7(1):100350. doi: 10.1016/j.esmoop.2021.100350. Epub 2021 Nov 27. ESMO Open. 2022. PMID: 34942438 Free PMC article.
The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature.
Botticelli A, Fabbri A, Roberto M, Alesini D, Cirillo A, D'Auria G, Krasniqi E, Marrucci E, Muratore M, Pantano F, Pizzuti L, Portarena I, Rossi R, Scagnoli S, Marchetti P. Botticelli A, et al. Among authors: fabbri a. Front Oncol. 2022 Feb 9;12:797157. doi: 10.3389/fonc.2022.797157. eCollection 2022. Front Oncol. 2022. PMID: 35223478 Free PMC article.
Impact of previous corticosteroid exposure on outcomes of patients receiving immune checkpoint inhibitors for advanced non-small cell lung cancer: a retrospective observational study.
Nelli F, Virtuoso A, Berrios JRG, Giannarelli D, Fabbri A, Marrucci E, Ruggeri EM. Nelli F, et al. Among authors: fabbri a. Cancer Chemother Pharmacol. 2022 Apr;89(4):529-537. doi: 10.1007/s00280-022-04416-4. Epub 2022 Mar 18. Cancer Chemother Pharmacol. 2022. PMID: 35301584
923 results